Sensorion SA (ALSEN.PA)

0.7060 -0.0040 (-0.56%) At close: 04:46PM CEST

Sensorion SA

375, rue du Professeur Joseph Blayac
Montpellier 34080
France
33 4 67 20 77 30
https://www.sensorion.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 57

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Nawal Ouzren	CEO & Director	N/A	N/A	1978
Mr. Bernd Schmidt	Chief Technical Officer	N/A	N/A	N/A
Dr. Geraldine Honnet M.D.	Chief Medical Officer	N/A	N/A	N/A
Ms. Christine Le Bec	Head of CMC Gene Therapy	N/A	N/A	N/A
Ms. Stephanie Filipe	Head of the Project Management Office	N/A	N/A	N/A
Mr. Laurent Desire	Head of Preclinical Development	N/A	N/A	N/A
Rachel Cooper	Head of Audiology	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. Its pipeline includes various products in the development stage for restoring, treating, and preventing inner ear related disorders. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2 clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2 clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, which is in Phase 2 clinical trial for the treatment of hearing preservation after cochlear implantation. It is also developing OTOF-GT (SENS-501), a gene therapy development program that has completed Phase 1 clinical trial to restore hearing in people living with Otoferlin deficiency; and GJB2-GT, a gene therapy development program, which is in pre-clinical trial to restore hearing in people living with hearing loss due to mutations in the GJB2 gene. The company was incorporated in 2009 and is headquartered in Montpellier, France.

Corporate governance

Sensorion SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.